Treasury Department officials are weighing potential restrictions on U.S. investments in China’s biotech sector, according to multiple sources familiar with internal discussions. The consideration points to a possible escalation of screening frameworks that already influence cross-border biotech transactions. While specific restriction mechanisms weren’t detailed, the reporting suggests active policy work that could affect licensing deals, equity investments, and other arrangements that connect U.S. capital with China development capacity. For biotech operators, the immediate implication is higher deal diligence complexity and potentially more uncertainty about timeline and approvals when transactions touch China-related biotech targets. This development arrives amid broader U.S. debate over national security and research risk, and it will likely intersect with existing investment screening approaches and compliance expectations for future partnerships.